A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Who May Qualify: - Male and female ≥50 to \<80 years of age at Screening Part II - Lp(a) ≥175 nmol/L at the screening visit, measured at the Central laboratory - Mild or moderate calcific aortic valve stenosis - At the randomization visit, participant must be optimally treated for existing CV risk factors Who Should NOT Join This Trial: - Severe calcific aortic valve stenosis - Uncontrolled hypertension - History of malignancy of any organ system - History of hemorrhagic stroke or other major bleeding - Platelet count ≤ LLN - Active liver disease or hepatic dysfunction - Significant kidney disease - Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may apply Always talk to your doctor about whether this trial is right for you.